bioAffinity Technologies, Inc. (BIAFW) Stock Analysis

Company Overview

bioAffinity Technologies, Inc. operates as a developer of non-invasive diagnostic laboratory tests designed to detect early-stage lung cancer and other pulmonary diseases utilizing flow cytometry and automated analysis within the United States. The company conducts its operations through two distinct segments: Diagnostic Research and Development, as well as Commercial, though the latter is not explicitly detailed in the provided data. The organization employs a workforce of 57 individuals to execute its technical and commercial objectives. While the specific sector and industry classifications are not disclosed in the available data, the lack of these designations suggests the company may operate in a niche or emerging market space where traditional categorization is fluid. The company's financial scale is defined by a trailing twelve-month revenue of $6.16M, which reflects a relatively small market presence. This revenue level, combined with a market capitalization that is not listed in the provided facts, indicates a micro-cap or small-cap profile typical of early-stage biotechnology firms. The employee count of 57 further underscores the lean operational structure often found in specialized diagnostic research companies. The absence of a reported market cap in the data implies significant volatility or a structure where traditional valuation metrics may not be immediately applicable, necessitating a focus on operational metrics rather than capitalization for assessment.

Financial Health

The company generated $6.16M in revenue over the trailing twelve months, yet it reported a net loss of $14,909,754, highlighting a substantial divergence between top-line activity and bottom-line profitability. This wide gap between revenue and net income reveals a cost structure where operating expenses significantly outweigh gross profits, a common characteristic in research and development-intensive phases. The company's EBITDA stood at $-10,067,672, indicating that even before interest and tax considerations, the core business operations are currently burning capital. Free cash flow for the period was $-4,933,569, which signifies a reliance on external financing or cash reserves to fund ongoing operations rather than self-sustaining cash generation. Despite these outflows, the company holds $6.45M in cash, providing a buffer against its $1.16M in debt, although the debt-to-equity ratio of 15.95 suggests a highly leveraged balance sheet relative to shareholder equity. Profitability metrics are severely constrained, with a gross margin of 31.4%, an operating margin of -196.9%, and a profit margin of -242.0%, all of which indicate that current operations are not covering their full cost bases. The return on equity is -301.8% and the return on assets is -75.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns. The current ratio stands at 2.60, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity despite the overall losses.

Valuation Assessment

Trailing P/E and forward P/E ratios are listed as N/A, which implies that the company has not generated positive earnings over the trailing twelve months to support a traditional earnings-based valuation multiple. The price-to-book ratio is 0.29, indicating that the market values the company at less than 30% of its book value, a metric often seen in distressed or turnaround situations rather than growth scenarios. Price-to-sales and EV/EBITDA metrics are also N/A, suggesting that these alternative valuation methods are either not applicable due to negative earnings or are not standard reporting conventions for this specific issuer in the current dataset. The stock's price has fluctuated within a 52-week range between a high of $0.46 and a low of $0.39. Without the current share price explicitly stated in the facts, the precise percentage deviation from the high or low cannot be calculated, but the range itself demonstrates significant price compression typical of small-cap biotech securities. The beta is 2.44, which means the stock is expected to be 2.44 times more volatile than the broader market, exposing investors to heightened price swings during periods of market stress.

Growth & Income

Revenue growth year-over-year declined by 27.8%, while earnings growth is N/A due to the absence of positive earnings to measure against prior periods. This contraction in revenue suggests a challenging sales environment or a decline in the commercialization of its diagnostic tests. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate for sustainability. Consequently, the company reinvests its limited cash flows and existing cash reserves into growth initiatives, research, and development rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion, significant profitability deficits, and a lack of current income generation, positioning the company as a high-risk investment dependent on future product approvals or market adoption to reverse its current trajectory.